Topical Gel Soothes Skin Rash for CRC Patients on EGFR Inhibitors
The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients with advanced colorectal cancer who were treated with an epidermal growth factor receptor (EGFR)-targeted drug, a randomized phase II trial showed. The 39 patients randomly assigned to receive a high-dose 0.1% formulation of LUT014 gel were twice […]
First Treatment Approved for Molluscum Contagiosum
Topical cantharidin (Ycanth) was approved as the first treatment specifically for molluscum contagiosum, the FDA announced. Molluscum contagiosum is a viral skin infection that affects as many as 6 million Americans, mostly children. The approval is to treat adults and pediatric patients as young as 2 years. The new treatment consists of a single-use applicator […]
FDA OKs Over-the-Counter Gel for Erectile Dysfunction
The FDA has granted over-the-counter marketing authorization to MED3000 (Eroxon), the first nonprescription topical gel for treating erectile dysfunction (ED), maker Futura Medical announced on Monday. According to the company, MED3000 has “a 10-minute onset of action” that sets it apart from prescription PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which typically require […]
Rare Skin Blistering Condition Gets First Drug Approved
The FDA granted the first drug approval for dystrophic epidermolysis bullosa (DEB), a topical gene therapy that treats the blistering wounds it causes, the agency announced Friday. The herpes-simplex virus type 1 vector-based gene therapy, Vyjuvek, was approved for patients ages 6 months and older with mutation in the COL7A1 (collagen type VII alpha 1 […]
Topical Gene Therapy Heals Blistering Skin Disease Lesions
A novel topical gene therapy healed most lesions among patients with dystrophic epidermolysis bullosa, a rare genetic blistering skin disease, the GEM-3 trial showed. Topical administration of beremagene geperpavec (B-VEC) led to complete healing of 67% of treated wounds as compared with 22% of those exposed to placebo at 6 months (P=0.002), reported M. Peter […]